Non-ST-elevation myocardial infarction: Difference between revisions
No edit summary |
|||
| Line 36: | Line 36: | ||
###ACC recs O2 for sats <90% (evidence indeterminant) | ###ACC recs O2 for sats <90% (evidence indeterminant) | ||
##Nitrates | ##Nitrates | ||
### | ###No mortality benefit | ||
### | ###Dilates coronary arts, decr preload, slight decr afterload | ||
### | ###Use of viagra within 24hr can lead to profound and prolonged vasodilation (and death) | ||
###B-block to avoid reflex | ###B-block to avoid reflex tachycardia | ||
##B-Blockers | ##B-Blockers | ||
###Goal HR is 50-60 | ###Goal HR is 50-60 | ||
###Contraindicated if HR<50 or SBP<90, acute CHF or | ###Contraindicated if HR<50 or SBP<90, acute CHF or PR>240ms | ||
###( | ###(Decreases progression from UA to MI by 13% | ||
### | ###Decr inotropic and chronotropic response to catechols | ||
###use dilt or verap if can't use b-block (nifedipine clearly harmful) | |||
###No IV BB in ED, PO within 24 H | |||
###use dilt or verap if | |||
### | |||
##ACE Inhibitor | ##ACE Inhibitor | ||
###start short-acting (captopril) | ###start short-acting (captopril) w/in 24hr of admission | ||
### | ###Reduces RR of 30 day mort by 7% | ||
### | ###Those w/ recent MI (esp ant) and LV dysfunction benefit most | ||
##Transfusion | ##Transfusion | ||
### | ###Transfuse to keep Hb>10 | ||
## | ##Magnesium | ||
###may use if pain after 3 doses of NTG | ###may use if pain after 3 doses of NTG | ||
### | ###Reduces pain and theoretically can decr HR and SBP and O2 demand | ||
### | ###Use associated with higher mortality in MI pts (and cause of higher mortality in CHF exacerbation pts) | ||
#Antiplatelet | #Antiplatelet | ||
##ASA | ##ASA | ||
### | ###Rec dose is 160-325mg chewed | ||
### | ###Reduces death from MI by 12.5-6.4% | ||
### | ###Should be used in all ACS unless contraindicated | ||
##Clopidogrel (plavix 300mg po then 75qd) | |||
##Clopidogrel (plavix | ###In addition to ASA | ||
### | ###Used over ticlopidine b/c faster onset & less s/e | ||
### | ###Mortality benifit with NSTEMI | ||
### | ###Main risk and contraind is bleeding | ||
### | ###CURE trial showed decr in CV death, MI or stroke by 9.3-11.5% | ||
##GPIIb/IIIa(-) = Eptifibatide (Integrillin) | |||
###CURE trial showed decr in CV death, MI or stroke | ###High-risk pts benefit most | ||
##GPIIb/IIIa(-) = Integrillin | ####PURSUIT trial found 30 day death or MI decr from 15.7% to 14.2% | ||
### | ###Incr ICH not seen w/ use | ||
###Benefit if early PCI is planned; ? to no benefit if PCI not planned | |||
###Reserved (if no pci) for positive trop or isch/ecg changes despite ASA, lovenox, b-block etc | |||
### | |||
### | |||
### | |||
### | |||
#Antithombotics | #Antithombotics | ||
## | ##Class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa | ||
##Unfractionated Heparin | |||
###Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s | |||
##LMWH: Enoxaparin (lovenox) | |||
###1mg/kg sc BID | |||
###Safer (ESSENCE showed 20% decr in death, MI or urgent revasc w/ LMWH vs UFH) | |||
###AHA recomends for mod & high risk UA/NSTEMI unless CABG w/in 24hr | |||
###Adjust for CrCl<30ml and extremes of weight | |||
###No need to monitor labs | |||
##Hirudin is approved only for pts w/ HIT | |||
### | |||
### | |||
## | |||
#Thrombolytics | #Thrombolytics | ||
## | ##Only useful for STEMI | ||
#Angiography | #Angiography indicated if: | ||
##Hemodynamic instability or cardiogenic shock | ##Hemodynamic instability or cardiogenic shock | ||
##Severe left ventricular dysfunction or heart failure | ##Severe left ventricular dysfunction or heart failure | ||
| Line 105: | Line 93: | ||
##New or worsening mitral regurgitation or new ventricular septal defect | ##New or worsening mitral regurgitation or new ventricular septal defect | ||
##Sustained ventricular arrhythmias | ##Sustained ventricular arrhythmias | ||
#Early (within 24hr) referral for angiography | #Early (within 24hr) referral for angiography if: | ||
##TIMI risk score greater than 2 | ##TIMI risk score greater than 2 | ||
##New or presumably new ST segment depression | ##New or presumably new ST segment depression | ||
Revision as of 22:40, 12 May 2011
Background
- 33% w/ confirmed MI have no CP on presentation (esp older, female, DM, CHF)
- 5% of NSTEMI will develop cardiogenic shock (60% mortality)
- Age >65 w/ MI and anemia had 33% reduction in 30 day mort if transfused to keep HCT >30
- Association between quantity of troponin and risk of death
Diagnosis
- ACS = STEMI, NSTEMI, UA
- Angina is considered unstable with 1 or more:
- Occurs for 1st time
- Occurs at rest
- Accelerating frequency or severity
- ECG is normal in 8% of all confirmed MI's
- Intensity of Rx should be based on likelihood that sx are due to acute coronary thombosis
TIMI RISK STRATIFICATION SCORE
- 1 point for each
- Age ≥65 years
- Presence of at least three risk factors for CHD
- Prior coronary stenosis of ≥50 percent
- Presence of ST segment deviation on admission ECG
- At least two anginal episodes in prior 24 hours
- Elevated serum cardiac biomarkers
- Use of aspirin in prior seven days
- Likelihood of mortality, new or recurrent MI, or require revascularization at 14 days
- Score of 0/1 - 4.7 percent
- Score of 2 - 8.3 percent
- Score of 3 - 13.2 percent
- Score of 4 - 19.9 percent
- Score of 5 - 26.2 percent
- Score of 6/7 - 40.9 percent
Treatment
- Anti-ischemia
- Oxygen
- ACC recs O2 for sats <90% (evidence indeterminant)
- Nitrates
- No mortality benefit
- Dilates coronary arts, decr preload, slight decr afterload
- Use of viagra within 24hr can lead to profound and prolonged vasodilation (and death)
- B-block to avoid reflex tachycardia
- B-Blockers
- Goal HR is 50-60
- Contraindicated if HR<50 or SBP<90, acute CHF or PR>240ms
- (Decreases progression from UA to MI by 13%
- Decr inotropic and chronotropic response to catechols
- use dilt or verap if can't use b-block (nifedipine clearly harmful)
- No IV BB in ED, PO within 24 H
- ACE Inhibitor
- start short-acting (captopril) w/in 24hr of admission
- Reduces RR of 30 day mort by 7%
- Those w/ recent MI (esp ant) and LV dysfunction benefit most
- Transfusion
- Transfuse to keep Hb>10
- Magnesium
- may use if pain after 3 doses of NTG
- Reduces pain and theoretically can decr HR and SBP and O2 demand
- Use associated with higher mortality in MI pts (and cause of higher mortality in CHF exacerbation pts)
- Oxygen
- Antiplatelet
- ASA
- Rec dose is 160-325mg chewed
- Reduces death from MI by 12.5-6.4%
- Should be used in all ACS unless contraindicated
- Clopidogrel (plavix 300mg po then 75qd)
- In addition to ASA
- Used over ticlopidine b/c faster onset & less s/e
- Mortality benifit with NSTEMI
- Main risk and contraind is bleeding
- CURE trial showed decr in CV death, MI or stroke by 9.3-11.5%
- GPIIb/IIIa(-) = Eptifibatide (Integrillin)
- High-risk pts benefit most
- PURSUIT trial found 30 day death or MI decr from 15.7% to 14.2%
- Incr ICH not seen w/ use
- Benefit if early PCI is planned; ? to no benefit if PCI not planned
- Reserved (if no pci) for positive trop or isch/ecg changes despite ASA, lovenox, b-block etc
- High-risk pts benefit most
- ASA
- Antithombotics
- Class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa
- Unfractionated Heparin
- Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s
- LMWH: Enoxaparin (lovenox)
- 1mg/kg sc BID
- Safer (ESSENCE showed 20% decr in death, MI or urgent revasc w/ LMWH vs UFH)
- AHA recomends for mod & high risk UA/NSTEMI unless CABG w/in 24hr
- Adjust for CrCl<30ml and extremes of weight
- No need to monitor labs
- Hirudin is approved only for pts w/ HIT
- Thrombolytics
- Only useful for STEMI
- Angiography indicated if:
- Hemodynamic instability or cardiogenic shock
- Severe left ventricular dysfunction or heart failure
- Recurrent or persistent rest angina despite intensive medical therapy
- New or worsening mitral regurgitation or new ventricular septal defect
- Sustained ventricular arrhythmias
- Early (within 24hr) referral for angiography if:
- TIMI risk score greater than 2
- New or presumably new ST segment depression
- Elevated cardiac enzymes
- Prior PCI within six months or prior CABG
- Recurrent angina or ischemia at rest or with low level activity despite intensive antiischemic therapy
- LVEF <40 percent
See Also
Cards: Cocaine CP
Source
EM Practice
UpToDate
